| Date | Title | | | 12/07/15 | Cipher Receives Health Canada Approval of (Pr)Beteflam™| – Will Represent Fourth Commercial Product in Cipher's Growing Canadian Dermatology Business –
MISSISSAUGA, ON, Dec. 7, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Health Canada has approved PrBeteflam™ (betamethasone valerate topical patch), a novel, patent-protected treatment of mild to moderate plaque psoriasis of the elbows and knees for a maximum duration of 30 days in adult patients.
"We are pleased to make Betefl... |
|  | | 11/25/15 | Cipher Pharmaceuticals to present at Piper Jaffray Healthcare Conference 2015| MISSISSAUGA, ON, Nov. 25, 2015 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, and Norman Evans, Chief Financial Officer, will present at the 27th Annual Piper Jaffray Healthcare Conference in New York City on Wednesday, December 2, 2015 at 3:30 PM ET. A live audio webcast will be available in the Investor Relations section of the Company's website at www.cipherpharma.... |
| | | 11/16/15 | Cipher to present at TD Securities 2015 Technology & Healthcare Conference| MISSISSAUGA, ON, Nov. 16, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will be presenting at the TD Securities 2015 Technology & Healthcare Conference in Toronto, Ontario on Friday, November 20, 2015 at 9:00AM ET.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (NASDAQ:CPHR; TSX:CPH) is a rapidly growing specialty pharmaceutical dermatology company with... |
| | | 11/04/15 | Cipher Reports Third Quarter Results| – Quarter Highlighted by 28% Revenue Growth, $2.3 Million in Cash Flow from Operations and Strong Advancement of Pre-Commercial Portfolio –
MISSISSAUGA, ON, Nov. 4, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and nine months ended September 30, 2015.
"Our 28% revenue growth in Q3 2015 was driven by our recent acquisition of Innocutis and continued growth of Epuris® & ... |
| | | 10/21/15 | Notice of Cipher Pharmaceuticals Inc. Q3 2015 Conference Call| MISSISSAUGA, ON, Oct. 21, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q3 2015 financial results on Wednesday, November 4, 2015.
Q3 2015 CONFERENCE CALL
WHEN: Wednesday, November 4, 2015 at 8:30AM ET
CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through www.cipherpharma.com or http://bit.ly/1LSI3hH. An archived replay of the webcast wil... |
| | | 10/05/15 | Cipher announces settlement in patent litigation for Absorica®| MISSISSAUGA, ON, Oct. 5, 2015 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Company, along with its partners, Ranbaxy Pharmaceuticals, Inc. ("Ranbaxy"), a Sun Pharma Company, and Galephar Pharmaceutical Research, Inc. ("Galephar"), have entered into a Settlement Agreement with Actavis Laboratories F1, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc. ("Actavis") that dismisses the patent litigation suit relating to ... |
| | | 08/14/15 | Cipher Reports Financial and Operational Results for Q2 2015| – Quarter Highlighted by Continued Solid Performance from Isotretinoin Products and Acquisition and Integration of Innocutis –
MISSISSAUGA, ON, Aug. 14, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended June 30, 2015.
Change in Presentation Currency
Effective April 1, 2015, Cipher changed its presentation currency from the Canadian dollar to the United States dollar as th... |
| | | 08/04/15 | Cipher Pharmaceuticals announces acceptance of 510(k) submission for Dermadexin™ by FDA| - Acceptance marks first regulatory filing with FDA since Absorica® in 2011 -
MISSISSAUGA, ON, Aug. 4, 2015 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that it has received an Acceptance Review Notification for its 510(k) submission for Dermadexin™ to the U.S. Food & Drug Administration ("FDA"). The Notification confirms that the submission contains all of the necessary elements and information needed to proceed with t... |
| | | 07/31/15 | Notice of Cipher Pharmaceuticals Inc. Q2 2015 Conference Call| MISSISSAUGA, ON, July 31, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q2 2015 financial results on Friday, August 14, 2015.
Q2 2015 CONFERENCE CALL
WHEN: Friday, August 14, 2015 at 8:30AM ET
CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through http://www.cipherpharma.com or http://cnw.ca/6U1ju. An archived replay of the webcast will be... |
| | | 07/30/15 | Cipher Pharmaceuticals Announces Successful Completion of Second Phase III for Ozenoxacin| - Company expects to submit Ozenoxacin for regulatory approval in Canada in the first quarter of 2016 -
MISSISSAUGA, ON, July 30, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Ferrer International SA ("Ferrer") successfully completed the second phase III clinical trial for Ozenoxacin, a topical treatment for adult and paediatric patients with impetigo, a highly contagious bacterial skin infection. Cipher acquired the Canadian co... |
| |
|
